XenoSTART, the preclinical division of The START Center for Cancer Research, and Minerva Imaging, a Denmark-based CRO/CDMO specialized in radiopharmaceuticals, unveiled an expanded strategic partnership designed to create an integrated platform for radiopharmaceutical drug development. This initiative is poised to accelerate innovation in oncology, particularly in metastatic prostate cancer and other high-burden indications such as breast and neuroendocrine tumors.
By merging XenoSTART's repository of clinically annotated patient-derived xenograft (PDX) models with Minerva Imaging's expertise in molecular imaging, radionuclide therapies, and GMP-certified manufacturing, the collaboration enables a seamless transition from preclinical research through clinical translation. Sponsors will benefit from an integrated, single-source solution for discovery, translational studies, and radiopharmaceutical manufacturing, with access to fresh patient tumor tissue, rapid model development, and clinically relevant data.
Nick Slack, CEO of START, described the partnership as delivering the “gold standard in translational oncology research,” with enhanced predictability and speed for the development of life-changing therapies. For Minerva Imaging, this alliance leverages its advanced imaging modalities (PET/CT, SPECT/CT, MRI) and extensive experience in oncology and molecular imaging, helping to accelerate drug candidates from bench to bedside.
XenoSTART’s unique PDX models, exclusively sourced from START’s global network, closely mirror real-world clinical scenarios, granting sponsors critical insights into resistance patterns and treatment histories. The initiative sets a new standard for radiopharmaceutical development by shortening timelines, mitigating risks, and increasing opportunities to deliver targeted cancer therapies to patients worldwide.